institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 3 days ago • loading... • Updated 3 days ago

Overviewing Pivotal Phase 3 TEMPLE Trial of Atogepant vs Topiramate: Jessica Ailani, MD

Summary by neurologylive.com

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

neurologylive.com

Overviewing Pivotal Phase 3 TEMPLE Trial of Atogepant vs Topiramate: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated3 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in 3 days ago on Thursday, July 3, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics